Yahoo
    NasdaqGS - Nasdaq Real Time Price USD

    GRAIL, Inc. (GRAL)

    143.43 -15.49 (-9.75%)
    At close: 4:00:01 PM EDT
    143.43 0.00 (0.00%)
    After hours: 4:28:08 PM EDT
    Trade GRAIL on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for GRAL

    What's happening with GRAL?

    6m ago     Powered by Yahoo Scout

    GRAIL is approaching its November 4 third-quarter results, with Galleri test adoption and regulatory progress central to the outlook. Zacks expects revenue growth but continued losses, while its model shows 0.00% Earnings ESPand a Zacks Rank of #4 (Sell). Management also plans a healthcare conference presentation on November 10.

    Powered by Yahoo Scout
    • Previous Close 158.92
    • Open 150.51
    • Bid 110.33 x 200
    • Ask 143.54 x 600
    • Day's Range 141.07 - 155.18
    • 52 Week Range 41.50 - 166.48
    • Volume 1,072,300
    • Avg. Volume 1,029,043
    • Market Cap (intraday) 6.406B
    • Beta (5Y Monthly) 2.84
    • PE Ratio (TTM) --
    • EPS (TTM) -9.70
    • Earnings Date Nov 4, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 132.56
    • Zacks Rating Bearish

    GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

    grail.com

    910

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Diagnostics & Research

    Industry

    More about GRAIL, Inc.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    GRAL
    67.58%
    S&P 500 (^GSPC)
    10.73%

    1-Year Return

    GRAL
    57.36%
    S&P 500 (^GSPC)
    11.11%

    3-Year Return

    GRAL
    928.17%
    S&P 500 (^GSPC)
    81.91%

    5-Year Return

    GRAL
    928.17%
    S&P 500 (^GSPC)
    64.59%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue 44.69M
    Earnings -110.25M
    Profit Margin -246.71%

    Q3

    FY25

    Q4

    FY25

    Q1

    FY26

    Q2

    FY26

    -100M
    -50M
    0
    -245.0%
    -240.0%
    -235.0%
    -230.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    74.00 Low
    132.56 Average
    143.43 Current
    180.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 10/13/2026
    Analyst Morgan Stanley
    Rating Action Maintains
    Rating Equal-Weight
    Price Action Raises
    Price Target 60 -> 120
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      -236.95%

    • Return on Assets (ttm)

      -12.03%

    • Return on Equity (ttm)

      -16.12%

    • Revenue (ttm)

      165.26M

    • Net Income Avi to Common (ttm)

      -391.59M

    • Diluted EPS (ttm)

      -9.70

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      861.61M

    • Total Debt/Equity (mrq)

      3.59%

    • Levered Free Cash Flow (ttm)

      -103.58M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    RVMD Revolution Medicines, Inc.
    191.31 +0.55%
    WGS GeneDx Holdings Corp.
    69.06 -2.76%
    NTRA Natera, Inc.
    414.30 -4.98%
    GH Guardant Health, Inc.
    178.80 -3.51%
    GPCR Structure Therapeutics Inc.
    21.87 -0.32%
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: